Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TapImmune to Present Clinical & Scientific Update at the 2015 Marcum Microcap Conference

MRKR

SEATTLE, May 20, 2015 /PRNewswire/ -- TapImmune (OTCQB:TPIV), a clinic stage Cancer Immunotherapy Company, announced today that Dr. Glynn Wilson will present at the 2015 Marcum MicroCap Conference held Wednesday, May 27, 2015 and Thursday, May 28, 2015, at the Grand Hyatt New York. 

The Company's presentation by is scheduled to begin at 3.30 p.m. ET on Thursday, May 28 and will be available via a live webcast. To access the webcast, go to http://wsw.com/webcast/marcum3/tpiv.  Following the presentation the webcast will be archived for 90 days.

The presentation will include an update on the progress of clinical programs.  Following two successful Phase I clinical studies in HER2/neu breast cancer and ovarian and breast cancer TapImmune is completing preparations for start of Phase II trials in 2015.  Please visit the Company's website at www.tapimmune.com for further details.

The annual Marcum MicroCap Conference is a showcase for public companies with less than $500 million in market capitalization. This year's keynote speaker will be Richard S. Fuld, Jr., Chairman of Matrix Advisors and former Chairman of Lehman Brothers.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastases, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatments.  

About the Marcum MicroCap Conference

The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis.  Industry sectors include Technology, Media & Internet; Software & Business Services; Life Science & Healthcare; Retail & Consumer Products; Energy & Natural Resources; and Industrials. The conference additionally includes a full agenda of panel discussions on issues of strategic importance to small cap issuers and investors, moderated by industry leaders.

The Marcum MicroCap Conference attracts fund managers and high net worth investors focusing on small cap equities. Over 2,000 participants from all segments of the microcap market attend each year, including  senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.

For complete information about the 2015 Marcum MicroCap Conference, visit www.marcumllp.com/microcap.

About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; and MarcumBuchanan Associates LLC.

CONTACTS:

TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541

PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1-646-863-6519

Sean Leous
Chief Communications Officer
+1-646-863-8998
www.pcgadvisory.com

J. Streicher Capital, LLC
Robert Giordano
+1-917-327-3938

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-to-present-clinical--scientific-update-at-the-2015-marcum-microcap-conference-300086386.html

SOURCE TapImmune Inc.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today